Most cited papers in Peripheral Neuropathies and Disorders
What are the most cited papers in Peripheral Neuropathies and Disorders?
The most cited paper in Peripheral Neuropathies and Disorders is "Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria" (Alan J. Thompson et al., 2017), with 8,265 citations. Next come "Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis" (6,993) and "Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”" (5,023).
Showing 50 of 99 papers. Every paper with more than 871 citations is listed.
| # | Paper | ||
|---|---|---|---|
| 1 | Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria Alan J. Thompson et al. · The Lancet Neurology | 21 Dec 2017 | 8,265 |
| 2 | Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis W. I. McDonald, Alistair Compston, Gilles Edan et al. · Annals of Neurology | 26 Jun 2001 | 6,993 |
| 3 | Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria” Chris H. Polman, Stephen C. Reingold, Gilles Edan et al. · Annals of Neurology | 10 Nov 2005 | 5,023 |
| 4 | International consensus diagnostic criteria for neuromyelitis optica spectrum disorders Dean M. Wingerchuk, Brenda Banwell, Jeffrey L. Bennett et al. · Neurology | 19 Jun 2015 | 4,664 |
| 5 | A clinical approach to diagnosis of autoimmune encephalitis Francesc Graus et al. · The Lancet Neurology | 20 Feb 2016 | 4,550 |
| 6 | Axonal Transection in the Lesions of Multiple Sclerosis Bruce D. Trapp, John W. Peterson, Richard M. Ransohoff et al. · New England Journal of Medicine | 29 Jan 1998 | 4,062 |
| 7 | Heterogeneity of multiple sclerosis lesions: Implications for the pathogenesis of demyelination Claudia Francesca Lucchinetti, Wolfgang Br�ck, Joseph E. Parisi et al. · Annals of Neurology | Jun 2000 | 3,370 |
| 8 | A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis Vanda A. Lennon, Dean M. Wingerchuk, Thomas J. Kryzer et al. · The Lancet | Dec 2004 | 3,258 |
| 9 | Multiple Sclerosis John H. Noseworthy, Claudia Francesca Lucchinetti, Moses Rodriguez et al. · New England Journal of Medicine | 28 Sep 2000 | 2,909 |
| 10 | Neurologic Features in Severe SARS-CoV-2 Infection Julie Helms, Stéphane Kremer, Hamid Merdji et al. · New England Journal of Medicine | 15 Apr 2020 | 2,798 |
| 11 | A new variant of Creutzfeldt-Jakob disease in the UK Robert G. Will, James W. Ironside, Martin Zeidler et al. · The Lancet | Apr 1996 | 2,714 |
| 12 | Revised diagnostic criteria for neuromyelitis optica Dean M. Wingerchuk, Vanda A. Lennon, Sean Joseph Pittock et al. · Neurology | May 2006 | 2,585 |
| 13 | Intramuscular interferon beta‐1a for disease progression in relapsing multiple sclerosis Lawrence D. Jacobs et al. · Annals of Neurology | Mar 1996 | 2,458 |
| 14 | Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis Josep O. Dalmau, Eric Lancaster, Eugenia Martínez‐Hernández et al. · The Lancet Neurology | 15 Dec 2010 | 2,457 |
| 15 | IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel Vanda A. Lennon, Thomas J. Kryzer, Sean Joseph Pittock et al. · The Journal of Experimental Medicine | 8 Aug 2005 | 2,299 |
| 16 | Guillain-Barré Syndrome outbreak associated with Zika virus infection in French Polynesia: a case-control study Van‐Mai Cao‐Lormeau et al. · The Lancet | 2 Mar 2016 | 2,266 |
| 17 | Immunopathology of multiple sclerosis Calliope Athena Dendrou, Lars H. Fugger, Manuel Alexander Friese · Nature reviews. Immunology | 7 Aug 2015 | 2,260 |
| 18 | Guidelines on the Use of Therapeutic Apheresis in Clinical Practice – Evidence‐Based Approach from the Writing Committee of the American Society for Apheresis: The Eighth Special Issue Anand Padmanabhan, Laura S. Connelly‐Smith, Nicole A. Aqui et al. · Journal of Clinical Apheresis | Jun 2019 | 2,235 |
| 19 | Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis Jeffrey A. Cohen, Frederik Barkhof, Gıancarlo Comı et al. · New England Journal of Medicine | 20 Jan 2010 | 2,217 |
| 20 | The spectrum of neuromyelitis optica Dean M. Wingerchuk, Vanda A. Lennon, Claudia Francesca Lucchinetti et al. · The Lancet Neurology | 14 Aug 2007 | 2,195 |
| 21 | Antiphospholipid syndrome: Clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients Ricard Cervera et al. · Arthritis & Rheumatism | Apr 2002 | 2,177 |
| 22 | Multiple sclerosis – a review Ruth Dobson, Gavin Giovannoni · European Journal of Neurology | 10 Oct 2018 | 2,167 |
| 23 | Cognitive impairment in multiple sclerosis Nancy D. Chiaravalloti, John DeLuca · The Lancet Neurology | 12 Nov 2008 | 2,107 |
| 24 | Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis Stephen L. Hauser et al. · New England Journal of Medicine | 21 Dec 2016 | 2,042 |
| 25 | Neurological associations of COVID-19 Mark A Ellul, Laura Benjamin, Bhagteshwar Singh et al. · The Lancet Neurology | 2 Jul 2020 | 1,993 |
| 26 | Assessment of current diagnostic criteria for Guillain-Barr� syndrome Arthur K. Asbury, David R. Cornblath · Annals of Neurology | 1990 | 1,921 |
| 27 | Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis Xavier Montalbán et al. · New England Journal of Medicine | 21 Dec 2016 | 1,913 |
| 28 | ANKYLOSING SPONDYLITIS AND HL-A 27 D. A. Brewerton, F. Dudley Hart, Anne Nicholls et al. · The Lancet | Apr 1973 | 1,872 |
| 29 | Cortical demyelination and diffuse white matter injury in multiple sclerosis Alexandra Kutzelnigg, Claudia Francesca Lucchinetti, Christine Stadelmann et al. · Brain | 17 Oct 2005 | 1,857 |
| 30 | Multiple sclerosis Alastair Compston, Alasdair J. Coles · The Lancet | Apr 2002 | 1,752 |
| 31 | Multiple Sclerosis: An Immune or Neurodegenerative Disorder? Bruce D. Trapp, Klaus‐Armin Nave · Annual Review of Neuroscience | 17 Jun 2008 | 1,742 |
| 32 | Guillain-Barré syndrome Richard AC Hughes, David R. Cornblath · The Lancet | Nov 2005 | 1,690 |
| 33 | Guillain-Barré syndrome Hugh John Willison, Bart C. Jacobs, Pieter A. van Doorn · The Lancet | 2 Mar 2016 | 1,606 |
| 34 | Experimental autoimmune encephalomyelitis (EAE) as a model for multiple sclerosis (MS) Cris S. Constantinescu, Nasr Farooqi, Kate O’Brien et al. · British Journal of Pharmacology | 4 Mar 2011 | 1,543 |
| 35 | Paresis Acquired in the Intensive Care Unit A Prospective Multicenter Study Bernard De Jonghe · JAMA | 11 Dec 2002 | 1,533 |
| 36 | Intramuscular Interferon Beta-1A Therapy Initiated during a First Demyelinating Event in Multiple Sclerosis Lawrence D. Jacobs, Roy W. Beck, Jack H. Simon et al. · New England Journal of Medicine | 28 Sep 2000 | 1,514 |
| 37 | Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology Roberta Magliozzi, Owain W. Howell, A. Vora et al. · Brain | 21 Nov 2006 | 1,466 |
| 38 | Multiple sclerosis Massimo Filippi, Amit Bar‐Or, Fredrik Piehl et al. · Nature Reviews Disease Primers | 8 Nov 2018 | 1,452 |
| 39 | Transected neurites, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions John W. Peterson, Lars Eirik Bø, Sverre Jarl Mørk et al. · Annals of Neurology | 31 Aug 2001 | 1,413 |
| 40 | Antibodies to Kv1 potassium channel-complex proteins leucine-rich, glioma inactivated 1 protein and contactin-associated protein-2 in limbic encephalitis, Morvan’s syndrome and acquired neuromyotonia Sarosh R. Irani, Sian K Alexander, Patrick Joseph Waters et al. · Brain | 27 Jul 2010 | 1,372 |
| 41 | Subacute meningoencephalitis in a subset of patients with AD after Aβ42 immunization Jean Marc Orgogozo, Sid Gilman, Jean‐François Dartigues et al. · Neurology | 8 Jul 2003 | 1,351 |
| 42 | Antibody-Mediated Encephalitis Josep O. Dalmau, Francesc Graus · New England Journal of Medicine | 28 Feb 2018 | 1,350 |
| 43 | Natalizumab plus Interferon Beta-1a for Relapsing Multiple Sclerosis Richard A. Rudick, William H. Stuart, Peter A. Calabresi et al. · New England Journal of Medicine | Mar 2006 | 1,347 |
| 44 | Relapses and Progression of Disability in Multiple Sclerosis Christian Confavreux, Sandra Vukusic, Thibault Moreau et al. · New England Journal of Medicine | 16 Nov 2000 | 1,318 |
| 45 | Fatigue in neurological disorders Abhijit Chaudhuri, Peter O. Behan · The Lancet | Mar 2004 | 1,302 |
| 46 | Guillain–Barré Syndrome Associated with SARS-CoV-2 Gianpaolo Toscano, Francesco Palmerini, Sabrina Ravaglia et al. · New England Journal of Medicine | 17 Apr 2020 | 1,289 |
| 47 | Guillain–Barré Syndrome Nobuhiro Yuki, Hans‐Peter Hartung · New England Journal of Medicine | 14 Jun 2012 | 1,265 |
| 48 | Myasthenia gravis: subgroup classification and therapeutic strategies Nils Erik Gilhus, Jan J.G.M. Verschuuren · The Lancet Neurology | 13 Sep 2015 | 1,262 |
| 49 | Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis Frederik Barkhof · Brain | Nov 1997 | 1,257 |
| 50 | A Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis David H. Miller, Omar Khan, William A. Sheremata et al. · New England Journal of Medicine | 2003 | 1,249 |
Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for a field when OpenAlex files it under one of the field's topics; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.